Novel materials which possess the ability to target liver cells

Expert Opinion on Drug Delivery

Volumn 9, Issue 6, 2012, Pages 649-656

  Chen, Zhipeng ^a   Xiao, Lu ^a   Li, Wei ^a   Liu, Wen ^a   Liu, Dan ^b   Xiao, Yan Yu ^b   Chen, Jun ^a   Liu, Xiao ^a   Li, Wei Dong ^a   Cai, Bao Chang ^a  

^a NANJING UNIVERSITY OF CHINESE MEDICINE   (China)

^b CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Hepatic non parenchymal cell; Hepatic parenchymal cell; Liver targeting; Novel material

Indexed keywords

ASIALOFETUIN; ASIALOGLYCOPROTEIN; BILE ACID; BIOMATERIAL; DEXTRAN DERIVATIVE; FLUORESCEIN ISOTHIOCYANATE; GLUCOSAMINE DERIVATIVE; GLYCYRRHETINIC ACID; LACTOBIONIC ACID; MANNOSE; MANNOSE RECEPTOR; PLATELET DERIVED GROWTH FACTOR;

CELL NUCLEUS; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG TARGETING; HUMAN; KUPFFER CELL; LIVER CELL; LIVER DISEASE; LIVER PARENCHYMA; LYSOSOME; MITOCHONDRION; REVIEW; STELLATE CELL;

ANIMALS; CHEMISTRY, PHARMACEUTICAL; DRUG DELIVERY SYSTEMS; EMULSIONS; HEPATIC STELLATE CELLS; HEPATOCYTES; HUMANS; KUPFFER CELLS; LIGANDS; LIPOSOMES; LIVER DISEASES; MICROSPHERES; PHARMACEUTICAL PREPARATIONS;

EID: 84862069266     PISSN: 17425247     EISSN: 17447593     Source Type: Journal    
DOI: 10.1517/17425247.2012.679261     Document Type: Review

References (57)

1. Wu J, Zern MA. Hepatic stellate cells, atarget for the treatment of liver fibrosis. J Gastroenterol 2000;35:665-7
2. Orfila C, Lepert JC, Alric L, et al. Expression of TNF-alpha and immunohistochemical distribution of hepatic macrophage surface markers in carbon tetrachloride-induced chronic liver injury in rats. Histochem J 1999;31:677-85
3. Mavier P, Mallat A. Perspectives in the treatment of liver fibrosis. J Hepatol 1995;111(22):5
4. Meijer DKF, Molema G. Targeting of drugs to the liver. Semin Liver Dis 1995;202(15):56
5. Kawakami S, Sato A, Nishikawa M, et al. Mannose receptor-mediated gene transfer into macrophages using novel mannosylated cationic liposomes. Gene Ther 2000;7:292
6. Sato A, Kawakami S, Yamada M, et al. Enhanced gene Transfection in macrophages using mannosylated cationic liposomes-polyethyleneimine-plasmid. DNA complexes. J Drug Target 2001;9:201
7. Nishikawa M, Takemura S, Yamashita F, et al. Pharmacokinetics and in vivo gene transfer of plasmid DNA complexed with mannosylated poly(L-lysine) in mice. J Drug Target 2000;8:29
8. Higuchi Y, Nishikawa M, Kawakami S, et al. Uptake characteristics of mannosylated and fucosylated bovine serum albumin in primary cultured rat sinusoidal endothelial cells and Kupffer cells. Int J Pharm 2004;287:147-54 (Pubitemid 39487252)
9. Bianucci AM, Shiellini F. A 3d model for the human hepatic asialoglycoprotein receptor (ASGP-R). J Biomol Struct Dyn 2000;18:435-51 (Pubitemid 32016927)
10. Wu DQ, Lu B, Chang C, et al. Galactosylated fluorescent labeled micelles as a liver targeting drug carrier. Biomaterials 2009;30:1363-71
11. Zheng H, Zhang XQ, Xiong FL, et al. Preparation, characterization, and tissue distribution in mice of lactosaminated carboxymethyl chitosan nanoparticles. Carbohydr Polymers 2011;83:1139-45
12. Zhang C, Ping Q, Ding Y. Synthesis and characterization of chitosan derivatives carrying galactose residues. Journal of Applied Polymer Science 2005;97:2161-7 (Pubitemid 41343462)
13. Wang SN, Deng YH, Xu Hui, et al. Synthesis of a novel galactosylated lipid and its application to the hepatocyte-selective targeting of liposomal doxorubicin. Eur JPharm Biopharm 2006;62:32-8
14. Kamruzzaman Selim KM, Ha YS, Kim SJ, et al. Surface modification of magnetite nanoparticles using lactobionic acid and their interaction with hepatocytes. Biomaterials 2007;28:710-16 (Pubitemid 44754877)
15. Keiichi M, Yoshihiro N, Yukihiko A, et al. In vitro gene delivery mediated by asialofetuin-appended cationic liposomes associated with gamma-cyclodextrin into hepatocytes. J Drug Deliv 2011, Article ID 476137, 1.
16. Gagandeep K. Asialofetuin-coated PLGA Nanoparticles for Targeting Hepatocytes. DSpace Software 2010;8:31
17. Qi XR, Yan WW, Shi J. Hepatocytes targeting of cationic liposomes modified with soybean sterylglucoside and polyethylene glycol. World J Gastroenterol 2005;11:4947-52 (Pubitemid 41227190)
18. Maitani Y, Kawano K, Yamado K, et al. Efficiency of liposomes surface-modified with soybean-derived sterylglucoside as aliver targeting carrier in Hep G2 cells. J Control Release 2001;75:381-9 (Pubitemid 32727267)
19. Asl MN, Hosseinzadeh H. Review of pharmacological effects of Glycyrrhiza sp. and its bioactive compounds. Phytother Res 2008;22:709-24 (Pubitemid 351955567)
20. Fiore C, Eisenhut M, Krausse R, et al. Antiviral effects of Glycyrrhiza species. Phytother Res 2008;22:141-8 (Pubitemid 351363230)
21. Mao SJ, Bi YQ, Jin H, et al. Preparation, characterization and uptake by primary cultured rat hepatocytes of liposomes surface-modified with glycyrrhetinic acid. Pharmazie 2007;62:614-19
22. Satomi Y, Nishino H, Shibata S. Glycyrrhetinic acid and related compounds induce G1 arrest and apoptosis in human hepatocellular carcinoma HepG2. Anti Cancer Res 2005;25:4043-7 (Pubitemid 41665183)
23. He ZY, Zheng Xi, Wu XH, et al. Development of glycyrrhetinic acid-modified stealth cationic liposomes for gene delivery. International Journal of Pharmaceutics 2010;397:147-54
24. Tian Q, Zhang CN, Wang XH, et al. Glycyrrhetinic acid-modified chitosan/ poly(ethylene glycol) nanoparticles for liver-targeted delivery. Biomaterials 2010;31:4748-56
25. Popielarski SR, Pun SH, Davis ME. A nanoparticle-based model delivery system to guide the rational design of gene delivery to the liver. 1. Synthesis and characterization. Bioconjug Chem 2005;16:1063-70 (Pubitemid 41368106)
26. Chen ZP, Zhu JB, Chen HX, et al. Synthesis of a novel polymer bile salts-(poly ethylene glycol) 2000-bile salts and its application to the liver-selective targeting of liposomal DDB. Drug Dev Ind Pharm 2010;36:657-65
27. East L, Isacke CM. The mannose receptor family. Biochim Biophys Acta 2002;1572:364-86 (Pubitemid 35246355)
28. Aswathy J, Sajith S, Manzoor K, et al. Mannosylated chitosan-zinc sulphide nanocrystals as fluorescent bioprobes for targeted cancer imaging. Carbohydr Polymers 2011;85:37-43
29. Rieger J, Freichels H, Imberty A, et al. Polyester nanoparticles presenting mannose residues: toward the development of new vaccine delivery systems combining biodegradability and targeting properties. Biomacromolecules 2009;10:651-7
30. Chuang VT, Hansen KU, Otagiri M. Pharmaceutical strategies utilizing recombinant human serum albumin. Pharm Res 2002;19:569-77 (Pubitemid 34553662)
31. Sungeun K, Jae MJ, Mee KH, et al. Differential receptor targeting of liver cells using 99mTc-neoglycosylated human serum albumins. Arch Pharm Res 2008;31:60-6
32. Kawakami S, Sato A, Nishikawa M, et al. Mannose receptor-mediated gene transfer into macrophages using novel mannosylated cationic liposomes. Gene Ther 2000;7:292
33. Beljaars L, Olinga P, Molema G, et al. Characteristics of the hepatic stellate cell-selective carrier mannose 6-phosphate modified albumin (M6P(28)-HSA). Liver 2001;21:320-8 (Pubitemid 32910556)
34. Sato A, Kawakami S, Yamada M, et al. Enhanced gene Transfection in macrophages using mannosylated cationic liposomes-polyethyleneimine-plasmid DNA complexes. J. Drug Target 2001;9:201
35. Ankita V, Pariyankar S, Ejaz A, et al. Ligand binding strategies of human serum albumin: how can the argo be utilized? Chirality 2010;22:77-87
36. Kenshiro H, Toru M, Hiroshi W, et al. Genetically engineered mannosylated-human serum albumin as a versatile carrier. Journal of Controlled Release 2010;145:9-16
37. Simard JR, Zunszain PA, Ha CE, et al. Locating high-affinity fatty acid-binding sites on albumin by x-ray crystallography and NMR spectroscopy. Proc Natl Acad Sci USA 2005;102:17958-63 (Pubitemid 41798484)
38. Yabe Y, Kobayashi N, Nishikawa M, et al. Pharmacokinetics and preventive effects of targeted catalase derivatives on hydrogen peroxide-induced injury in perfused rat liver. Pharm Res 2002;19:1815-21 (Pubitemid 36016027)
39. Jeong JM, Hong MK, Lee J, et al. 99mTc-neolactosylated human serum albumin for imaging the hepatic asialoglycoprotein receptor. Bioconjug Chem 2004a;15:850-5 (Pubitemid 38981960)
40. Jeong JM, Hong MK, Kim YJ, et al. Development of 99mTc-neomannosyl human serum albumin (99mTc-MSA) as a novel receptor binding agent for sentinel lymph node imaging. Nucl Med Commun 2004b;25:1211-17
41. Guo J, Friedman SL. Hepatic fibrogenesis. Semin Liver Dis 2007;27:413-26 (Pubitemid 350071841)
42. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 2005;115:209-18 (Pubitemid 40385459)
43. Arthur MJ. Reversibility of liver fibrosis and cirrhosis following treatment for hepatitis C. Gastroenterology 2002;122:1525-8 (Pubitemid 34465193)
44. Issa R, Zhou X, Constandinou CM, et al. Spontaneous recovery from micronodular cirrhosis: evidence for incomplete resolution associated with matrix cross-linking. Gastroenterology 2004;126:1795-808 (Pubitemid 38736345)
45. Muriel P, Moreno MG, Hernandez MC, et al. Resolution of liver fibrosis in chronic CCl4 administration in the rat after discontinuation of treatment: effect of silymarin, silibinin, colchicine and trimethylcolchicinic acid. Basic Clin Pharmacol Toxicol 2005;96:375-80 (Pubitemid 40676591)
46. Breitkopf K, Roeyen C, Sawitza I, et al. Expression patterns of PDGF-A -B, -C and -D and the PDGF-receptors alpha and beta in activated rat hepatic stellate cells (HSC). Cytokine 2005;31:349-57 (Pubitemid 41188056)
47. Novosyadlyy R, Tron K, Dudas J, et al. Expression and regulation of the insulin-like growth factor axis components in rat liver myofibroblasts. J Cell Physiol 2004;199:388-98 (Pubitemid 38580435)
48. Greupink R, Bakker HI, Reker-Smit C, et al. Studies on the targeted delivery of the antifibrogenic compound mycophenolic acid to the hepatic stellate cell. J Hepatol 2005;43:884-92 (Pubitemid 41414515)
49. Greupink R, Bakker HI, Van GH, et al. Mannose-6-phosphate/insulin-like growth factor-II receptors may represent a target for the selective delivery of mycophenolic acid to fibrogenic cells. Pharm Res 2006;23:1827-34 (Pubitemid 44200546)
50. Greupink R, Bakker HI, Bouma W, et al. The antiproliferative drug doxorubicin inhibits liver fibrosis in bile duct-ligated rats and can be selectively delivered to hepatic stellate cells in vivo. J Pharmacol Exp Ther 2006;317:514-21
51. Greupink R, Reker-Smit C, Proost JH, et al. Pharmacokinetics of a hepatic stellate cell-targeted doxorubicin construct in bile duct-ligated rats. Biochem Pharmacol 2007;73:1455-62 (Pubitemid 46452578)
52. Hagens WI, Mattos A, Greupink R, et al. Targeting 15d-prostaglandin J2 to hepatic stellate cells: two options evaluated. Pharm Res 2007;24:566-74 (Pubitemid 46295161)
53. Hagens WI, Beljaars L, Mann DA, et al. Cellular targeting of the apoptosis-inducing compound gliotoxin to fibrotic rat livers. J Pharmacol Exp Ther 2008;324:902-10 (Pubitemid 351397843)
54. Adrian JE, Kamps JA, Poelstra K, et al. Delivery of viral vectors to hepatic stellate cells in fibrotic livers using HVJ envelopes fused with targeted liposomes. J Drug Target 2007;15:75-82 (Pubitemid 47161334)
55. Gonzalo T, Talman EG, Van DV, et al. Selective targeting of pentoxifylline to hepatic stellate cells using a novel platinum-based linker technology. J Control Release 2006;111:193-203 (Pubitemid 43290008)
56. Rachmawati H, Reker-Smit C, Lub-de Hooge MN, et al. Chemical modification of interleukin-10 with mannose 6-phosphate groups yields a liver-selective cytokine. Drug Metab Dispos 2007;35:814-21 (Pubitemid 46641553)
57. Moreno M, Gonzalo T, Kok RJ, et al. Reduction of advanced liver fibrosis by short-term targeted delivery of an angiotensin receptor blocker to hepatic stellate cells in rats. Hepatology 2010;51:942-52